Overview

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sa

Status:
NOT_YET_RECRUITING

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to look at the effectiveness of giving a combination of chemotherapy, immunotherapy, radiation therapy, and surgery to treat soft tissue sarcomas that can be removed by surgery. Researchers want to find out if this treatment combination can extend the time it takes for the disease to relapse (come back after treatment). The safety of this treatment combination will also be studied.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Genentech, Inc.

Treatments:

atezolizumab
Doxorubicin